Apricus Biosciences, Inc. (Nasdaq: APRI) announced its intent to file a New Drug Submission ("NDS") in Canada for MycoVa, the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE